Sign in with your email address username.


[Editorial] Neuraminidase inhibitors for influenza: a call for better research

On Oct 8, the Academy of Medical Sciences and the Wellcome Trust (AMS/WT) published a timely report on the use of neuraminidase inhibitor (NAI) antiviral drugs in seasonal and pandemic influenza treatment and prophylaxis. As winter approaches in the UK, the debate about whether the benefit of routine use of NAIs outweighs the risks of side-effects, such as nausea and vomiting continues; a meta-analysis published in The Lancet in January explored this issue in oseltamivir use for seasonal influenza.